Phase I study of single-dose BMY-28100, a new oral cephalosporin.

The objective of this Phase I study was to evaluate the safety, tolerance, and pharmacokinetics of BMY-28100 in 36 male subjects after the administration of single oral doses of 250, 500, and 1,000 mg. The subjects were divided into groups of 12 per dose group. All subjects completed the study, and...

Descripció completa

Dades bibliogràfiques

Publicat a:	Antimicrob Agents Chemother
Autors principals:	Barbhaiya, R H, Gleason, C R, Shyu, W C, Wilber, R B, Martin, R R, Pittman, K A
Format:	Artigo
Idioma:	Inglês
Publicat:	American Society for Microbiology (ASM) 1990
Matèries:	Research Article
Accés en línia:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC171556/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2327766/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.34.2.202
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!